The stock of Arbutus Biopharma Corp (NASDAQ:ABUS) hit a new 52-week low and has $2.48 target or 10.00% below today’s $2.75 share price. The 6 months bearish chart indicates high risk for the $145.61M company. The 1-year low was reported on Nov, 10 by Barchart.com. If the $2.48 price target is reached, the company will be worth $14.56 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 1.79% or $0.05 on November 10, hitting $2.75. About 173,068 shares traded hands or 6.07% up from the average. Arbutus Biopharma Corp (NASDAQ:ABUS) has declined 44.55% since April 8, 2016 and is downtrending. It has underperformed by 50.20% the S&P500.
Arbutus Biopharma Corp (NASDAQ:ABUS) Ratings Coverage
Out of 5 analysts covering Arbutus Biopharma (NASDAQ:ABUS), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. $20.0 is the highest target while $2.75 is the lowest. The $13.75 average target is 400.00% above today’s ($2.75) stock price. Arbutus Biopharma has been the topic of 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Chardan Capital Markets upgraded Arbutus Biopharma Corp (NASDAQ:ABUS) on Thursday, June 16 to “Neutral” rating. The rating was initiated by Wedbush with “Outperform” on Friday, August 7. Chardan Capital Markets downgraded the shares of ABUS in a report on Friday, July 8 to “Sell” rating. RBC Capital Markets maintained the shares of ABUS in a report on Friday, November 6 with “Outperform” rating. As per Wednesday, September 2, the company rating was initiated by JMP Securities. The firm has “Outperform” rating by Wedbush given on Friday, August 7. The firm has “Neutral” rating given on Friday, October 14 by Chardan Capital Markets. Chardan Capital Markets initiated it with “Sell” rating and $3.25 target price in Monday, May 16 report. Leerink Swann downgraded the stock to “Market Perform” rating in Friday, August 5 report.
According to Zacks Investment Research, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.”
Another recent and important Arbutus Biopharma Corp (NASDAQ:ABUS) news was published by Marketwatch.com which published an article titled: “Virtual Stock Exchange” on December 29, 2013.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.